SPC216
Dúpílúmab
Status:
VeittApplication date:
5.1.2018Application published:
15.2.2018Grant published:
15.3.2019
Max expiry date:
27.3.2033Medicine name:
DupixentMedicine for children:
Yes
Timeline
Today
5.1.2018Application
15.2.2018Publication
15.3.2019Registration
27.3.2033Expires
Marketing license
IS authorization number:
EU/1/17/1229/001-008Date:
10.10.2017
Foreign authorization number:
EU/1/17/1229Date:
26.9.2017
Owner
Name:
Regeneron Pharmaceuticals, Inc.Address:
777 Old Saw Mill River Road, Tarrytown, NY US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2356151